Repurposed leukemia drug tested for Tough-to-Treat lung cancer
NCT ID NCT07140016
Summary
This early-phase study is testing the safety and tolerability of gilteritinib, a drug already approved for a type of leukemia, in adults with advanced ALK-positive non-small cell lung cancer (NSCLC) whose cancer has stopped responding to prior ALK inhibitor treatments. About 40 participants will take gilteritinib tablets daily in 28-day cycles, starting at a lower dose that may increase if tolerated. The main goal is to understand the side effects and determine safe dosing for this new use of the medication.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-SMALL CELL LUNG CANCER (NSCLC) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Hackensack University Medical Center
RECRUITINGHackensack, New Jersey, 07601, United States
-
OSF Health Care
RECRUITINGPeoria, Illinois, 61637, United States
-
Site ES34006
RECRUITINGMadrid, Spain
-
Site ES34008
RECRUITINGMálaga, Spain
-
Site ES34011
RECRUITINGMadrid, Spain
-
University of Michigan Health Systems
RECRUITINGAnn Arbor, Michigan, 48109, United States
-
Virginia Cancer Specialists PC
RECRUITINGFairfax, Virginia, 22031, United States
-
Washington University School of Medicine
RECRUITINGSt Louis, Missouri, 63110, United States
Conditions
Explore the condition pages connected to this study.